{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-005406","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.403414+00:00","generated_at":"2026-05-26T22:10:37.355711+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vanda Q4 2024 revenue $53.2M (+17% YoY); guides 2025 rev $210-250M","bullets":["Q4 2024 net loss $4.9M vs $2.4M loss in Q4 2023; Fanapt sales $26.6M (+18% YoY).","Full year 2024 revenue $198.8M (+3%); net loss $18.9M vs net income $2.5M in 2023.","2025 revenue guidance $210-250M; targets psychiatry portfolio >$750M by 2030.","Bysanti NDA for bipolar/schizophrenia expected Q1 2025; Tradipitant NDA for motion sickness submitted Q4 2024.","Imsidolimab BLA for generalized pustular psoriasis expected in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-005406","json":"https://secwatch.observer/filing/0001628280-25-005406.json","markdown":"https://secwatch.observer/filing/0001628280-25-005406.md","text":"https://secwatch.observer/filing/0001628280-25-005406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828025005406/0001628280-25-005406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828025005406/vnda-20250213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:10:37.355711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}